Steve Speller. Substances that have the potential to:- do good do harm.

Slides:



Advertisements
Similar presentations
The Role of Government in Encouraging a High Standard of Ethics in the Healthcare Sector: Indonesia Experience Prof. Agus Purwadianto Senior Adviser to.
Advertisements

PwC Medical Device Compliance Survey Discussion of Survey Results.
Division: EIDD WTO TBT Workshop on Good Regulatory Practice March 2008 Focus on Transparency and Consultation.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
European Union of Medical Specialists November 18, 2011 Conference John McLoughlin Chairman, European Medical Technology Industry Association (EUCOMED)
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
The critical role of Evolving Information Systems and the need for Standardised Coding.
Spanish Code of Practice for the Promotion of Medicines CONFIDENTIAL "International congresses, including booth materials and panels, controls related.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
November  The Case for a Marketing Code of Practice  The Marketing Code of Practice Journey  The Parts to the Code  So What?  Examples & Scenarios.
ZHRC/HTI Financial Management Training
LIMITLESS POTENTIAL | LIMITLESS OPPORTUNITIES | LIMITLESS IMPACT Copyright University of Reading IMPACT AND THE LIFE SCIENCES Anthony Atkin (Research Impact.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Legislative Review Regulated Health Professions Act Manitoba Chiropractors’ Association AGM March 22, 2009 Dr. Dan Wilson.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
Consumer Code for Home Builders Noel Hunter Chairman 1.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
SA Code of Practice for the Marketing of Health Products Marketing Ethics and what does this mean for an HCP? Dr Haseena Gani Executive Officer Sept 2013.
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Access to Clinical Expertise Steve Bain David Powell Jemma Hughes Paula Jeffries.
Briefing to the Health Portfolio Committee: Operational Activities and Budgets KP Matshidze Acting CEO and Registrar Council for Medical Schemes XX August.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
Small-Scale Embedded Generation (AMEU and its Work Group Input) Gerrit Teunissen 18 April 2013.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
Purchasing Ethics and Vendor Relations
Trade-related policies and access to medicines ICTSD Consultation on trade policy coherence and access to medicines Geneva November 7 th 2006,
EXPERIENCES IN SOUTH AFRICA WITH THE INTRODUCTION OF PHARMACEUTICAL PRICING LEGISLATION Zokufa HZ, Pillay T Pharmaceutical Policy and Planning, Department.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
THE PHARMACY STAKEHOLDERS FORUM Presenter: Mr Sham Moodley 6 August 2008 Oral Presentation to the Portfolio Committee on Health Public Hearing on Medicines.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Latest in Health Law…. SAPRAA June Key pieces of legislation Health Charter & BB BEE Medicines & Related Substance Act, regulations & Code Medical.
The Importance of Promoting Codes of Ethics to Stakeholders.
Codes of Conduct The International Pharmaceutical Regulatory & Compliance Congress and Best Practice Forum 6 June 2007 Heather Simmonds Director Prescription.
+ Role of Industry in Clinical Care, Research, and Education.
EFPIA and IFPMA Code Compliance Strategies Richard BERGSTRÖM Chair, EFPIA Code Steering Committee Chair, IFPMA Code Compliance Network Presentation at.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Setting the Scene: The Role of Ethics and Compliance in the Biopharmaceutical Market.
Medicines and Related Substances Amendment Bill 2008 Presented by: Abeda Williams 5 August 2008 Pharmaceutical Industry Association of South Africa.
COCIR Code of Conduct Nicole DENJOY COCIR Secretary General.
Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Medicines and Related Substances Amendment Bill 2008 Pharmaceutical Task Group: Industry Marketing Code Steering Committee Presented by: Maureen Kirkman.
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
Portfolio Committee for Health Medicines and Related Substances Amendment Bill (06/08/08) IMSA represents Research Based Pharmaceutical Companies.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
ERIC REURTS Draft SA Marketing Code. Marketing Code Steering Committee PIASA - Pharmaceutical Industry Association NAPM – National Association of Pharmaceutical.
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.
Audit Oversight in an Emerging Economy Bernard Peter Agulhas Chief Executive Officer Independent Regulatory Board for Auditors.
Transparency of payments to healthcare professionals: ABPI plans for a central platform for individual disclosures 2016 June 2014.
1 The Implementation of Fair Market Value What can we learn from recent enforcement actions? Debjit Ghosh Life Sciences Advisory Services Huron Consulting.
The IVD Australia Code of Conduct Edition 2.1
Disclosure UK Talking about Transparency.
Disclosure UK Talking about Transparency.
Trade-related policies and access to medicines
Health Technology Assessment
IMPLEMENTATION OF THE SOUTH AFRICAN LANGUAGE PRACTITIONERS COUNCIL ACT, 2014 (Act No. 8 of 2014) PRESENTED TO THE SELECT COMMITTEE ON EDUCATION & RECREATION.
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Raising the Standards in European Homeopathy
Industry Induction Course
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Coalition Sample Code of Ethics
Presentation transcript:

Steve Speller

Substances that have the potential to:- do good do harm

Why is it needed in South Africa ? To Protect Consumers

The complexity of three types of consumers People Animals Healthcare Professionals Direct Indirect Direct

As suppliers of health care products what do we try to do to customers ? Inform Them? Influence Them?

What is our intent?

Off label promotion... Selective use of clinical trial information... Incentive schemes Hospitality practices....

Pharma industry in the news Polish Newsweek: Pharmaceutical corporations spend millions of dollars on presents for the doctors who prescribe their patented medicines. When buying medicines, we have to pay not only for our health, but also for costly gifts. Milan (Reuters): Italian police are investigating a unit of a pharma company for allegedly offering illegal incentives to doctors and medical staff to prescribe its drugs British Medical Journal May: Who pays for the pizza? Re-defining the relationships between doctors and drug companies.

Obligations for all..... A Code of Practice for the marketing of healthcare products is required to provide a basis for the ethical marketing of health products Requirement for reliable scientific information to be available to health care practitioners and patients/consumers To enhance the rationale use of health products and fair competition in their marketing Preserve the independence of the decisions taken by healthcare professionals

Code of Marketing Practice Fundamental Principle self regulation

A long journey July 2007 – Marketing Steering Committee 2009 – SAMED & SALDA join Feb 2010 – Interim Board of the MCA Oct 2010 – Agreed version of the Code May 2011 – Agreed MoU March 12 constitution signed AGM

Scope of the Code The Code is a collaborative effort by various sub-sectors in the marketing of health products Builds on the experiences and principles endorsed by these sub- sectors Code has been established after many years of consultation: at first, only ethical products were regulated by the Code but now, many categories of products included Innovative medicines Generics Veterinary medicines OTC products Medical devices Laboratory diagnostics

Current Trade Associations subscribing to the Code PIASA: Pharmaceutical Industry Association of South Africa NAPM: National Association of Pharmaceutical manufacturers IMSA: Innovative Medicines South Africa SMASA: Self-Medication Manufacturers Association of South Africa PHARMISA: Pharmaceuticals made in South Africa SAAHA: South African Animal Health Association SAMED: South African Medical Device Industry Association SALDA: South African Laboratory Diagnostics Association Support for the initiative and enforcement: Pharmaceutical Wholesalers and Distributers Pharmaceutical Society of Southern Africa

Who is the Code Applicable to? licence holders, their agents, contractors, third party distributors /marketers and/or contracted events organisers any member of medical, dental, pharmacy, nursing or allied health professions any seller of health products who may prescribe, purchase, supply, administer, loan or lease a health product or recommend the use thereof is not applicable to wholesalers, distributors (excluding distributors of medical devices) and logistics companies except to the extent that they may influence the demand for health products Note: Logistics service providers forum and PSSA has endorsed the Code 14

What the Code does not cover? 18A: “bonus system, rebate system or any other incentives scheme” 18B: Sampling 22G: Pricing, dispensing fees, logistics fee Proposal to DoH: Gaps on legislation 15SA Marketing Code ( )

Scope of the Code Marketing & promotion of medicines to healthcare professionals Part A Marketing & promotion of medicines to consumers Part B Devices Part C Enforcement Part D - Replace ASA appendix A & H - Guidelines

ACTIVITIES TO HCP’S: APPLICABLE TO ALL HEALTH PRODUCTS 17SA Marketing Code ( )

Healthcare Sales Reps(C15) Training Interviews / access to HCP: No inducements No fees paid No donations to charities or in lieu of hospitality Mislead as to company identity No inconvenience Report AE PI provided for new products and then afterwards should be available on request 18

Interactions with HCP (C17) Hospitality, venue of meeting Scientific and educational Hospitality secondary to meeting Appropriate venue* Modest – not more the HCP would pay for themself No spouse or other guest Reasonable honorarium for speaker Local CPD – reasonable travel to HCP outside major cities Overseas congress / speakers Business class travel only for incoming and outgoing faculty members (i.e. HCPs presenting at congress, educational events or local CPD accredited events). Selection of attendees should be transparent and open to scrutiny Payment to congress or organisers not HCP unless proof of payment No recreational or sporting activities allowed 19

Interactions with HCP (C17) Other matters: No standalone social or sporting events Consultancy services Genuine service Declaration by HCP Written agreements Honararium – fair market value and relate to activity performed Can’t pay for room rentals

Inducements (*) C18 No gifts, rebates to HCP to induce use of products Gifts / promotional items Inexpensive and value of R 300 (medical devices cap of R 2500 / practise or institution) Educational and scientific benefit patient / practice No cash or equivalent No personal use Scientific medical reference books, journals, anatomical models : For individual practising HCP or practises, < R incl of VAT/year For training or academic institutions, < R incl of VAT/year The value of medical devices should not exceed R300 inclusive of VAT / per item with a cap of R 2500 / practise or institution Promo items can be branded with company or product logo Cultural gifts – not allowed by SAMED / SALDA (*)Subject to company / corporate policies 21

Other activities (C18) Competition (C18.5) Based on medical / product knowledge Prize relevant to practice The maximum is R If prize is congress sponsorship – cover conference fees, accommodation and travel for the winner only. Donations / grants to HCP (C18.6) Supporting healthcare or research Documented Not inducement Not paid to HCP Corporate Social Responsibility (C18.7) Support a charitable organizations charitable contributions are not for marketing Not an incentive to prescribe any health product 22

MCA Structure MCA Adjudicating Panel Adjudicating Committee Appeal Panel Appeal Committee Legal Panel Executive Officer 23 Appointed by Board Appointed by EO for specific complaint Code Technical Advisory Committee

Overall: Key MCA objectives Awareness of the Code: General roles and responsibilities of the MCA Industry healthcare groups Government: health and CPA ASA HCPs Allied medical professionals Patients Consumers Training of all Industry stakeholders on the content of the Code Internal and external providers: must get our certification Paper based E based Getting certification Implementation of the Code: Self regulation Legislated environment Enforcement and sanctions

Complaint Process Company to Company MCASanctionDoH No resolution Breach of Act 101, legal mechanisms 25

Is it having an impact? Yes BUT early days Still lots to do re appointment of Executive Officer finalisation of training and certification process regulations influence healthcare professionals

Still required.... The Medicines and Related Substances Control Act 101, 1965 will be the vehicle for the Code enforcement Via Regulation 18 C of Act 101, 1965 Desire of the Associations to have the Code enforced by law Working with the DoH to seek approval of proposed wording for the update of the Regulations

Conclusions Years of dedication of the Marketing Code Steering Committee to develop a new Code Marketing Code Authority is now established Procedures are defined to formalise the Authority With new Associations being added to the existing groups, the Constitution will be signed by all Associations Essential to have fair and balanced promotion of medicines for both Healthcare professionals and patients Essential to retain the self regulatory status of the Code in line with other highly functional international Codes

Annual General Meeting 12 th September 9am – 11.45am Cedar Park Hotel 120 Western Service Road Woodmead Guest Speaker – Dr Anban Pillay